

Journal of Antimicrobial Chemotherapy

jac.oxfordjournals.org

J. Antimicrob. Chemother. (2007) 59 (4): 587-590. doi: 10.1093/jac/dkm006
First published online: February 16, 2007

The increasing use of silver-based products as antimicrobial agents: a useful development or a cause for concern?

Ian Chopra*

+ Author Affiliations

*Tel: +44-113-343-5604; Fax: +44-113-343-5638; E-mail:
i.chopra@leeds.ac.uk

Abstract

Silver first gained regulatory approval for use as an antimicrobial agent in the early 20th century, but its usage diminished with the introduction of antibiotics in the 1940s. Recently, however, topical silver has gained popularity once again, principally in the management of open wounds. This has been largely due to the spread of methicillin-resistant *Staphylococcus aureus* and the resultant reduction in first-line antibiotic prescribing. The increase in the use of topical silver has raised issues concerning silver resistance, together with questions about the standardization of antimicrobial testing methods for silver. Issues related to silver product testing include a failure to establish standard procedures for determining MIC values, an absence of recognized breakpoints, a lack of

Oxford Index

About the Index

 Show related links

release and the measurement of inhibitory activity. The clinical incidence of silver resistance remains low, and emergence of resistance can be minimized if the level of silver ions released from products is high and the bactericidal activity rapid.

Key words [silver](#) [resistance](#) [bacteria](#) [healing](#) [wounds](#)

Introduction

The use of silver in wound management can be traced back to the 18th century, during which silver nitrate (AgNO_3) was used in the treatment of ulcers.¹ The antimicrobial activity of the silver ions was first identified in the 19th century,

and colloidal silver was accepted by the US Food and Drug Administration (FDA) as being effective for wound management in the 1920s.^{2,3} However, after the introduction of penicillin in the 1940s, antibiotics became the standard treatment for bacterial infections and the use of silver diminished.

Silver began to be used again for the management of burn patients in the 1960s, this time in the form of 0.5% AgNO₃ solution.^{4,5} AgNO₃ was combined with a sulphonamide antibiotic in 1968 to produce silver sulfadiazine (SSD) cream, which created a broader spectrum silver-based antibacterial that continued to be prescribed mostly for the management of burns.^{6,7} More recently, clinicians have turned to wound dressings that incorporate varying levels of silver, because the emergence and increase of antibiotic-resistant bacteria have resulted in clinical limitations in the prescription of antibiotics.⁸

At the same time, a greater variety of silver-based dressings have become available, such as Acticoat (Smith and Nephew) and Actisorb (Johnson and Johnson),⁹ which offer wider therapeutic options. As well as infection management, these include the stimulation of healing in indolent wounds, prophylactic use for patients at risk of contracting a wound infection, and the management of critically colonized wounds.¹⁰ In addition, silver-based vascular and urinary catheters have now entered clinical use.⁹ As the use of silver and the number of available silver-based products increases, it is becoming more important to ensure that standard procedures are developed to measure the efficacy of each product. It is also essential to answer questions concerning mechanisms and clinical risk related to silver resistance.

Susceptibility standards for silver-based products

Since it was first established that the killing of pathogens ceased when the serum concentration of penicillin dropped below the MIC,¹¹ the determination of pharmacological indices has been pivotal in the comparison of antimicrobial agents and in the development of optimal dosing regimens. Hence, in the field of antibiotics, the assignment of MIC values and breakpoints is essential, particularly when considering the susceptibility of organisms to systemic and topical agents and the incidence of microbial resistance.^{12,13} It is necessary to define these pharmacological parameters in order to predict antimicrobial efficacy in the treatment of infection.

MIC values and categorical breakpoints (traditionally, susceptible, intermediate and resistant) are now defined by various professional organizations such as the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the CLSI (formerly the NCCLS). However, breakpoints for silver ions have not been agreed,^{14,15} and determination of MIC₅₀ and MIC₉₀ values, which are commonplace in the evaluation of the susceptibility of bacteria to antibiotics, have not been adopted by those studying silver-containing products.¹⁶

Where silver microbial susceptibility studies have been performed, the authors have assigned their own breakpoints to delineate susceptible and resistant strains. Most of these studies have produced different MIC data for AgNO₃, and this demonstrates the extent of variation that currently exists with regard to the pharmacological parameters of silver. For instance, results from the two studies that explored MIC values for *Staphylococcus aureus* (around 100 strains) range from 8 to 80 mg/L.^{15,17} Similarly, the two largest studies examining silver ion MIC values for approximately 100 strains of *Pseudomonas aeruginosa* produced a range from 8 to 70 mg/L.^{18,19}

Standardization of antimicrobial testing methods for silver

A further challenge exists because of a lack of standardization for silver ion antimicrobial testing methods. In part, this is due to complex solubility issues affecting the bioavailability of silver ions through formation of various silver-halide anionic complexes. This means that silver ion availability may be influenced by the sodium chloride content of the microbiological medium used for susceptibility testing.¹⁴ Some researchers have used Mueller-Hinton media to test for silver susceptibility in a manner analogous to CLSI guidelines for antibiotics, but a variety of other media have also been adopted and the effects of these on final measurements with silver is not known.

To complicate matters further, most silver dressings make use of different delivery systems that release silver ions in a variety of concentrations. The question of whether one antimicrobial agent is necessarily representative of others is a recognized challenge for the standardization of antibiotic breakpoints.²⁰ However, the issue for modern silver-based dressings is far more complex. Thomas and McCubbin^{21,22} tested 10 different silver-based dressings to compare their antimicrobial activity. Only four of these

incorporated the same basic form of (ionic) silver as their active ingredient. The remainder used completely different types of silver. Also, none of the dressings incorporated silver within the same basic structure. All the dressings utilized different materials and silver ion release methods. The authors concluded that 'while total silver content is important, other factors also influence a dressing's ability to kill microorganisms. These include the distribution of silver within the dressing, its chemical and physical form and the dressing's affinity for moisture'.

Mechanisms of silver resistance

To date, there are less than 20 published reports of silver resistance in bacteria and only a few of these include data that help clarify resistance mechanisms.²³ McHugh et al.²⁴ described the first instance when a silver-resistant strain of *Salmonella typhimurium* emerged in a hospital burns unit. It was reported that a silver-resistant determinant occurred on a conjugally transferable plasmid, which also encoded resistance to mercuric chloride, ampicillin, chloramphenicol, tetracycline, streptomycin and sulphonamides. Subsequently, this plasmid was named pMG101 and defined as a 180 kb plasmid belonging to the IncH1 incompatibility class. The region of pMG101 that confers inducible silver resistance has been sequenced and the function of the gene products deduced. The silver-resistance determinant contains seven genes and two open-reading frames of unknown function.^{14,25}

Early clinical studies identified silver resistance in other members of the Enterobacteriaceae, but the resistance phenotype was unstable in the absence of silver selection pressure.^{26,27} This could reflect reversion of chromosomal mutations conferring silver resistance, especially if they imposed fitness costs, or possibly loss of plasmids encoding resistance. Unfortunately, no further genetic or biochemical studies were undertaken on the isolates described by these groups.

Bridges et al.²⁸ isolated silver-resistant *P. aeruginosa* from burn patients. A loss of resistance on subculture suggests that resistance may have been plasmid-mediated.

Deshpande and Chopade²⁹ discovered a 54 kb plasmid (pUPI199) encoding resistance to silver nitrate in an environmental isolate of *Acinetobacter baumannii* that was transferable to *Escherichia coli* by conjugation. The plasmid did not encode resistance to other metal ions or antibiotics. The mechanism of silver resistance may have involved

intracellular detoxification of silver ions by pUPI199.

Li et al.³⁰ concluded that silver resistance in *E. coli* may depend on a mechanism that works in combination with porin loss. They described the characterization of silver-resistant mutants of *E. coli* selected by stepwise exposure of sensitive strains to AgNO₃ or SSD and reported that enhanced efflux of silver ions was detected in silver-resistant mutants. This suggests that activation of an endogenous silver efflux system together with porin mutations provides the basis for silver resistance.

Subsequent work by Gupta et al.³¹ proposed that candidates for the endogenous chromosomal genes could be genomic homologues of the *silA* and *silP* genes known to have a role in the efflux of silver ions mediated by plasmid pMG101. An ATP-dependent copper efflux protein that also mediates removal of silver ions was identified as the major component conferring tolerance to silver in *Candida albicans*.³²

High-level, single-step, target-based mutation to silver resistance is unlikely because of the multifaceted mode of action of the silver ion. This hypothesis is supported by a study that examined the frequency of spontaneous mutation to silver-containing compounds.³³ The authors were unable to recover silver-resistant mutants of *S. aureus* (i.e. frequency <10⁻⁹) when SSD was used as the selecting agent. This contrasts with the situation for mutational resistance in bacteria arising in single antibiotic targets where spontaneous mutation frequencies of about 10⁻⁸ are usually recorded.¹⁶

Silver-based products and the clinical reality of resistance

There is no doubt that bacterial resistance to silver can occur.^{9,14} However, whether resistance is a threat in the clinical environment is unclear. The lack of standardized methods to determine bacterial susceptibility to silver, and the absence of recognized breakpoints, certainly complicate interpretation of silver susceptibility and resistance data. If an attempt to define breakpoints for silver was made, the wide variation in product delivery systems and silver formulations would present unique challenges above and beyond those normally encountered when setting breakpoints for antibiotics.

Silver-based dressings release different amounts of silver ions in different ways via different materials. There is no standard methodology currently available that will ensure a

uniform release and concentration of silver ions from different products on which to base MIC values and breakpoints. When the effectiveness of different silver-based dressings against a range of bacteria has been determined, a wide range of data has been generated.^{21,22,34} Despite these difficulties, there have been fewer than 20 documented reports of bacterial resistance to silver since 1975.

The increased use of silver dressings has occurred because alternatives are required to replace antibiotics in the management of infected wounds.^{10,21,22,34,35} Until more clarity is available concerning MIC levels and breakpoints relating to silver, clinicians should take the common sense measure of using silver dressings that are effective against both Gram-positive and Gram-negative bacteria, with a proven high degree of silver ion release and rapid bactericidal activity.³⁴⁻³⁶ Some of the higher silver release formulations produce ionic silver concentrations that reach 70–100 parts per million when measured in ionic water and kill relevant bacteria within 30 min.³⁶⁻³⁸ They also provide a continuous supply of new ionized silver molecules.^{37,38} There is also evidence to support their efficacy in the clinical environment.³⁹

Dressings that release low levels of silver ions are likely to be more dangerous in terms of selection for resistance, especially if the silver ion concentration is sublethal. Faster acting dressings will inevitably present less risk because organisms are more likely to be killed, thereby eliminating possibilities for enrichment of the resistant population through growth and division, especially in the context of mutational development of resistance.

Conclusions

There is a need for silver MIC levels and breakpoints to be developed and standardized. However, even though silver resistance has been documented, current evidence suggests the clinical threat is low. The two most likely mechanisms of silver resistance are plasmid acquisition and gene mutation to decrease silver ion uptake or promote efflux. There is no direct evidence that silver resistance mechanisms confer cross-resistance to antibiotics. However, genetic linkage of silver resistance genes and antibiotic resistance genes has been reported in the context of plasmid-mediated silver resistance.

Some silver-based dressings appear to provide an effective

alternative to antibiotics in the management of wound infection. However, dressings that release low levels of silver ions are likely to be more problematic in terms of selection for resistance, especially if the silver concentration is sublethal. In order to minimize the risk of silver resistance, clinicians should choose dressings that release high levels of silver ions and that demonstrate rapid bactericidal activity.

Transparency declarations

I received an educational grant from Smith and Nephew Research to review the literature and prepare this article.

© The Author 2007. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

References

1. Klassen III. Historical review of the use of silver in the treatment of burns. I. Early uses. *Burns* 2000;26:117–30.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
2. Hugo WB, Russell AD. Types of antimicrobial agents. In: Russell AD, Hugo WB, Auliffe CA, editors. *Oxford, UK: Blackwell Scientific Publications; 1982. p. 9–106. Principles and Practice of Disinfection, Preservation and Sterilisation.*
[Google Scholar](#)
3. Dowling BJ, DeSanti L. Effects of silver on wound management. *Wounds* 2001;13:4. Suppl A.
[Google Scholar](#)
4. Price WB, Wood M. Silver nitrate burn dressing. Treatment of seventy burned persons. *Am J Surg* 1966;112:674–80.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
5. Meyer CA, Brontano J, Craven DL, et al. Treatment of large human burns with 0.5 per cent silver nitrate solution. *Arch Surg* 1965;90:812–67.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
6. Fay CL, Jr. Silver sulfadiazine: a new topical therapy for Pseudomonas in burns. Therapy of Pseudomonas infection in burns. *Arch Surg* 1968;96:184–8.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
7. George N, Foccoli L, Muller M. Silverase (silver sulfadiazine and chlorhexidine) activity against 200 clinical isolates. *Burns* 1997;23:493–5.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
8. Gemmell CC, Edwards DJ, Fraize AB, et al. Guidelines for the prophylaxis and treatment of methicillin-resistant *Staphylococcus aureus* (MRSA) infections in the UK. *J Antimicrob Chemother* 2006;57:589–608.
[Abstract/FREE Full Text](#)

9. Silver S, Phung LT, Silver C. Silver as biocides in burn and wound dressings and bacterial resistance to silver compounds. *J Ind Microbiol Biotechnol* 2006;33:627–34.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
10. Sibbald RC, Osted H, Schultz GS, et al. Preparing the wound bed 2002: focus on infection and inflammation. *Ostomy Wound Manage* 2003;49:23–51.
[Medline](#) [Google Scholar](#)
11. Eagle H, Fleischman B, Musselman AD. The bactericidal action of penicillin in vivo: the participation of the host, and the slow recovery of the surviving organisms. *Ann Intern Med* 1950;33:544–71.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
12. Struelens ML. The problem of resistance. In: Finch RC, Greenwood D, Morby SC, et al., editors. *Edinburgh: Churchill Livingstone; 2003.* p. 25–47. *Antibiotic and Chemotherapy—Eighth Edition.*
[Google Scholar](#)
13. Kahlmeter G. Laboratory control of antimicrobial therapy. In: Finch RC, Greenwood D, Morby SC, et al., editors. *Edinburgh: Churchill Livingstone; 2003.* p. 112–9. *Antibiotic and Chemotherapy—Eighth Edition.*
[Google Scholar](#)
14. Silver S. Bacterial silver resistance: molecular biology and uses and misuses of silver compounds. *FEMS Microbiol Rev* 2003;27:341–53.
[Abstract/FREE Full Text](#)
15. Ho A, Gaydon O. Occurrence of resistance to antibiotics, metals, and glycopeptides in clinical strains of *Staphylococcus* spp. *Arch Med Res* 2003;34:130–6.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
16. O'Neill AL, Cheng J. Preclinical evaluation of novel antibacterial agents by microbiological and molecular techniques. *Expert Opin Investig Drugs* 2004;13:1045–63.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
17. Hamilton Miller JM, Shah S, Smith C. Silver sulfadiazine: a comprehensive in vitro reassessment. *Chemotherapy* 1993;39:405–9.
[Medline](#) [Web of Science](#) [Google Scholar](#)
18. Vesichka B, Chikhar S, Savova M. Heavy metal resistance in clinical isolates of *Pseudomonas aeruginosa*. *Folia Microbiol (Praha)* 1989;34:448–52.
[Google Scholar](#)
19. de Vicente A, Aviles M, Cedeno JC, et al. Resistance to antibiotics and heavy metals of *Pseudomonas aeruginosa* isolated from natural waters. *J Appl Bacteriol* 1990;68:625–32.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
20. MacCowan AB, Wise P. Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests. *J Antimicrob Chemother* 2001;48:17–28. Suppl 1.
[Abstract](#)

21. Thomas S, McCubbin B. A comparison of the antimicrobial effects of four silver-containing dressings on three organisms. *J Wound Care* 2003;12:101–7.
[CrossRef](#) [Medline](#) [Google Scholar](#)
22. Thomas S, McCubbin B. An in vitro analysis of the antimicrobial properties of 10 silver-containing dressings. *J Wound Care* 2003;12:305.
[Medline](#) [Google Scholar](#)
23. Percival SL, Bowler PC, Russell D. Bacterial resistance to silver in wound care. *J Hosp Infect* 2005;60:1–7.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
24. Mellish CE, Medlering BC, Hopkins CC, et al. *Salmonella typhimurium* resistant to silver nitrate, chloramphenicol, and ampicillin. *Lancet* 1975;1:235–40.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
25. Gupta A, Metevik K, Le JE, et al. Molecular basis for resistance to silver cations in *Salmonella*. *Nat Med* 1999;5:183–8.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
26. Anonon DL, Mac BL, Bailey M. Instability and linkage of silver resistance, lactose fermentation, and colony structure in *Enterobacter cloacae* from burn wounds. *J Clin Pathol* 1976;29:441–3.
[Abstract/FREE Full Text](#)
27. Hendy AT, Stewart JO. Silver-resistant *Enterobacteriaceae* from hospital patients. *Can J Microbiol* 1979;25:915–21.
[Medline](#) [Web of Science](#) [Google Scholar](#)
28. Bridges K, Kildan A, Leubner EL, et al. Gentamicin- and silver-resistant *Pseudomonas* in a burns unit. *Br Med J* 1979;1:446–9.
[Abstract/FREE Full Text](#)
29. Deshpande JM, Chandra BA. Plasmid-mediated silver resistance in *Acinetobacter baumannii*. *Biometals* 1994;7:49–56.
[Medline](#) [Google Scholar](#)
30. Li YZ, Nikaido H, Williams KE. Silver-resistant mutants of *Escherichia coli* display active efflux of Ag⁺ and are deficient in porins. *J Bacteriol* 1997;179:6127–32.
[Abstract/FREE Full Text](#)
31. Gupta A, Rhung LT, Taylor DE, et al. Diversity of silver resistance genes in IncH incompatibility group plasmids. *Microbiology* 2001;147:3393–402.
[Abstract/FREE Full Text](#)
32. Biggle BL, Kumamoto CA. Role of a *Candida albicans* P1-type ATPase in resistance to copper and silver ion toxicity. *J Bacteriol* 2000;182:4899–905.
[Abstract/FREE Full Text](#)
33. Meale PA, Hamilton Miller JM, Brumfitt W. Comparison of the in vitro activities of the topical antimicrobials azelaic acid, nitrofurazone, silver sulphadiazine and mupirocin against methicillin-resistant *Staphylococcus aureus*. *J Antimicrob Chemother* 1992;29:661–8.
[Abstract/FREE Full Text](#)

34. Strabel B, Schelling M, Takacs M, et al. Nanocrystalline silver dressings as an efficient anti-MRSA barrier: a new solution to an increasing problem. *J Hosp Infect* 2005;60:226–30.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
35. Fong J, Wood F, Fowler B. A silver-coated dressing reduces the incidence of early burn wound cellulitis and associated costs of inpatient treatment: comparative patient care audits. *Burns* 2005;31:562–7.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
36. Yin HQ, Langford B, Burrell PE. Comparative evaluation of the antimicrobial activity of ACTICOAT antimicrobial barrier dressing. *J Burn Care Rehabil* 1999;20:195–200.
[CrossRef](#) [Medline](#) [Web of Science](#) [Google Scholar](#)
37. Quinnton JC. The role of silver technology in wound healing, part 2: why is nanocrystalline silver superior? *Wounds* 2001;13:5–10. Suppl B2.
[Google Scholar](#)
38. Burrell PE. A scientific perspective on the use of topical silver preparations. *Ostomy Wound Manage* 2003;49:19–24. Suppl 5A.
[Medline](#) [Google Scholar](#)
39. Sibbald RC, Brown AC, Coutts B, et al. Screening evaluation of an ionized nanocrystalline silver dressing in chronic wound care. *Ostomy Wound Manage* 2001;47:38–43.
[Medline](#) [Google Scholar](#)

Articles citing this article

Bacterial antimicrobial metal ion resistance

J Med Microbiol (2015) 64 (Pt_5): 471-497

[Abstract](#) [Full Text \(HTML\)](#) [Full Text \(PDF\)](#)

Silver resistance in Gram-negative bacteria: a dissection of endogenous and exogenous mechanisms

J Antimicrob Chemother (2015) 70 (4): 1037-1046

[Abstract](#) [Full Text \(HTML\)](#) [Full Text \(PDF\)](#)

The elements of life and medicines

Phil Trans R Soc A (2015) 373 (2037): 20140182

[Abstract](#) [Full Text \(HTML\)](#) [Full Text \(PDF\)](#)

Pyocyanin Production by *Pseudomonas aeruginosa* Confers Resistance to Ionic Silver

Antimicrob. Agents Chemother. (2014) 58 (9): 5492-5499

[Abstract](#) [Full Text \(HTML\)](#) [Full Text \(PDF\)](#)

X-Ray Absorption Near-Edge Structure (XANES) Spectroscopy Study of the Interaction of Silver Ions with *Staphylococcus aureus*, *Listeria monocytogenes*, and *Escherichia coli*

Appl. Environ. Microbiol. (2013) 79 (20): 6385-6390

[Abstract](#) [Full Text \(HTML\)](#) [Full Text \(PDF\)](#)

Interaction of Silver Nanoparticles with Serum Proteins Affects Their Antimicrobial Activity In Vivo

Antimicrob. Agents Chemother. (2013) 57 (10): 4945-4955

[Abstract](#) [Full Text \(HTML\)](#) [Full Text \(PDF\)](#)

The silver cation (Ag⁺): antistaphylococcal activity, mode of action and resistance studies

J Antimicrob Chemother (2013) 68 (1): 131-138

[Abstract](#) [Full Text \(HTML\)](#) [Full Text \(PDF\)](#)

Standardizing an in vitro procedure for the evaluation of the antimicrobial activity of wound dressings and the assessment of three wound dressings

J Antimicrob Chemother (2012) 67 (7): 1697-1700

[Abstract](#) [Full Text \(HTML\)](#) [Full Text \(PDF\)](#)

2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections

Clinical Infectious Diseases (2012) 54 (12): e132-e173

[Abstract](#) [Full Text \(HTML\)](#) [Full Text \(PDF\)](#)

Antibacterial burst-release from minimal Ag-containing plasma polymer coatings

J R Soc Interface (2011) 8 (60): 1019-1030

[Abstract](#) [Full Text \(HTML\)](#) [Full Text \(PDF\)](#)

Bacteriophage versus antimicrobial agents for the treatment of murine burn wound infection caused by *Klebsiella pneumoniae* B5055

J Med Microbiol (2011) 60 (2): 205-210

[Abstract](#) [Full Text \(HTML\)](#) [Full Text \(PDF\)](#)

Inhibition of Large-Conductance Ca²⁺-Activated K⁺ Channels by Nanomolar Concentrations of Ag⁺

Mol. Pharmacol. (2010) 78 (5): 952-960

[Abstract](#) [Full Text \(HTML\)](#) [Full Text \(PDF\)](#)

Silver Coordination Polymers for Prevention of Implant Infection: Thiol Interaction, Impact on Respiratory Chain Enzymes, and Hydroxyl Radical Induction

Antimicrob. Agents Chemother. (2010) 54 (10): 4208-4218

[Abstract](#) [Full Text \(HTML\)](#) [Full Text \(PDF\)](#)

An Update on Pharmacological Interventions for Diabetic Foot Ulcers

Foot Ankle Spec (2010) 3 (5): 285-302

[Abstract](#) [Full Text \(PDF\)](#)

Rechargeable Antibacterial and Antifungal Polymeric Silver Sulfadiazines

Journal of Bioactive and Compatible Polymers (2009) 24 (4): 350-367

[Abstract](#) [Full Text \(PDF\)](#)

Antimicrobial surface functionalization of plastic catheters by silver nanoparticles

J Antimicrob Chemother (2008) 61 (4): 869-876

[Abstract](#) [Full Text \(HTML\)](#) [Full Text \(PDF\)](#)

Comment on: The increasing use of silver-based products as antimicrobial agents: a useful development or a cause for concern?

J Antimicrob Chemother (2007) 60 (2): 447

[Full Text \(HTML\)](#) [Full Text \(PDF\)](#)

The increasing use of silver-based products as antimicrobial agents: a useful development or a cause for concern?--author's response

Online publication 11 February 2015, DOI: 10.1093/jac/dkx001, 0305-7453

Copyright © 2015 British Society for Antimicrobial Chemotherapy

[Full Text \(HTML\)](#) [Full Text \(PDF\)](#)

[Site Map](#) [Privacy Policy](#) [Cookie Policy](#) [Legal Notices](#) [Frequently Asked Questions](#)

Other Oxford University Press sites: